Correlation Between Biomarin Pharmaceutical and I Mab

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Biomarin Pharmaceutical and I Mab at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Biomarin Pharmaceutical and I Mab into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Biomarin Pharmaceutical and I Mab, you can compare the effects of market volatilities on Biomarin Pharmaceutical and I Mab and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Biomarin Pharmaceutical with a short position of I Mab. Check out your portfolio center. Please also check ongoing floating volatility patterns of Biomarin Pharmaceutical and I Mab.

Diversification Opportunities for Biomarin Pharmaceutical and I Mab

-0.01
  Correlation Coefficient

Good diversification

The 3 months correlation between Biomarin and IMAB is -0.01. Overlapping area represents the amount of risk that can be diversified away by holding Biomarin Pharmaceutical and I Mab in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on I Mab and Biomarin Pharmaceutical is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Biomarin Pharmaceutical are associated (or correlated) with I Mab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of I Mab has no effect on the direction of Biomarin Pharmaceutical i.e., Biomarin Pharmaceutical and I Mab go up and down completely randomly.

Pair Corralation between Biomarin Pharmaceutical and I Mab

Given the investment horizon of 90 days Biomarin Pharmaceutical is expected to under-perform the I Mab. But the stock apears to be less risky and, when comparing its historical volatility, Biomarin Pharmaceutical is 2.06 times less risky than I Mab. The stock trades about -0.19 of its potential returns per unit of risk. The I Mab is currently generating about -0.04 of returns per unit of risk over similar time horizon. If you would invest  117.00  in I Mab on August 28, 2024 and sell it today you would lose (23.00) from holding I Mab or give up 19.66% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Biomarin Pharmaceutical  vs.  I Mab

 Performance 
       Timeline  
Biomarin Pharmaceutical 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Biomarin Pharmaceutical has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.
I Mab 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days I Mab has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

Biomarin Pharmaceutical and I Mab Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Biomarin Pharmaceutical and I Mab

The main advantage of trading using opposite Biomarin Pharmaceutical and I Mab positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Biomarin Pharmaceutical position performs unexpectedly, I Mab can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in I Mab will offset losses from the drop in I Mab's long position.
The idea behind Biomarin Pharmaceutical and I Mab pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Other Complementary Tools

Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins